GNRH1 and ovarian carcinoma: In vitro studies support this, showing that LHRHR agonists like Buserelin and [D-Ala6] GnRH inhibit ovarian cancer cell growth in a time- and dose-dependent manner, while the antagonist Antide reverses this inhibition [24].